Certara Evidence & Access

◾️As a global research consultancy, we're committed to providing the highest level of scientific evidence on the value of medicines and health technologies◾️

[Certara Evidence & Access @CertaraAccess]

Our team combines unmatched technical capabilities and advanced analytic methods to inform key decisions and maximize your product’s impact. Subscribe to our blog to uncover how we drive impactful science from bench to market: https://t.co/lRr5xtkwKZ

[Certara Evidence & Access @CertaraAccess]

Our team combines unmatched technical capabilities and advanced analytic methods to inform key decisions and maximize your product’s impact. Subscribe to our blog to uncover how we drive impactful science from bench to market: https://t.co/lRr5xtkwKZ

[Certara Evidence & Access @CertaraAccess]

To optimally position your products, portfolio or company, it is critical to understand the various forces that shape the US specialty drug landscape in 2021. To help, we are pleased to share the Key Trends in US Specialty Pharmacy and Access report here: https://t.co/pQl1TtKQvX

[Certara Evidence & Access @CertaraAccess]

Where are you on the journey of launching innovative payment models? Learn how we assessed novel payment innovation such as performance contracts, annuities, reinsurance/stop-loss, and subscription models in our whitepaper: https://t.co/Y9qLwolqLx

[Certara Evidence & Access @CertaraAccess]

ICYMI: You can still access our #ISPOREurope on-demand presentation, posters, and other information via our virtual booth at your convenience: https://t.co/500wL7tEvg
#realworldevidence #realworlddata

[Certara Evidence & Access @CertaraAccess]

#ISPOREurope has concluded but our posters and on-demand presentation will be available through the end of the year for registered meeting attendees via the virtual exhibit gallery: https://t.co/500wL7c3DI
#realworldevidence #realworlddata

[Certara Evidence & Access @CertaraAccess]

#ISPOREurope is coming to a close but our posters and on-demand presentation will remain accessible to registered attendees through the end of the year. Access our posters and presentations via our virtual event booth: https://t.co/500wL7c3DI
#realworldevidence #realworlddata

[Certara Evidence & Access @CertaraAccess]

Learn how we’re optimizing evidence and value from bench to market. Connect with our team via our #ISPOREurope virtual booth to schedule a time to discuss your value and access questions and challenges: https://t.co/500wL7tEvg #realworldevidence #realworlddata

[Certara Evidence & Access @CertaraAccess]

Join us at #ISPOREurope! Registered attendees can browse our library of iposters & watch an on-demand presentation by Patrizia Berto in the Developments in HTA Processes and Methods session. Access the event portal: https://t.co/500wL7c3DI #realworldevidence #realworlddata

[Certara Evidence & Access @CertaraAccess]

One key takeaway from our recent research: There is a growing desire among payers to see the appraisal of pharmaceuticals based on quality-adjusted life-years, like that of ICER, the nation’s self-proclaimed independent watchdog on drug pricing. Read more https://t.co/DykUceIKhl

[Certara Evidence & Access @CertaraAccess]

#ISPOREurope kicks off next week, but we’re already making connections. Connect with our representatives via our virtual booth to schedule time to discuss your value and access questions and challenges: https://t.co/500wL7tEvg

[Certara Evidence & Access @CertaraAccess]

Our third whitepaper in our series on disruptive trends in U.S. #marketaccess reveals that insurers now broadly support a role for cost-effectiveness for drug value assessments. Read it here: https://t.co/TCHqKs5cQb

[Certara Evidence & Access @CertaraAccess]

Our #ISPOREurope booth is now open! View our resources and learn more about how we’re optimizing evidence and value from bench to market: https://t.co/VmHqmKCNaU
#ISPOR2020 #realworldevidence #realworlddata

[Certara Evidence & Access @CertaraAccess]

Are you seeking proven expertise on the shifting pricing and reimbursement environment in the U.S.? Connect with @Certara experts at #BIOEUROPE: https://t.co/yGZnArY3ZI

[Certara Evidence & Access @CertaraAccess]

If you’re attending #BIOEUROPE, we want to meet with you. Connect with @Uli_neumann for a commercial assessment of new opportunities or pipeline assets https://t.co/yGZnArY3ZI

[Certara Evidence & Access @CertaraAccess]

Are we betting too much on #vaccines? "While all effort should be made in vaccine development, we must not forget the cocktail approach's value," says @WilliamFeehery. Read the article: https://t.co/A1bKgPfzl4

[Certara @Certara]

#ICYMI - Last week @CertaraAccess provided a webinar on payment pressures in U.S. specialty. Watch the on-demand recording to learn more about major trends in US specialty pharmacy and to receive guidance on future policies: https://t.co/3fO8EvFNMm
#marketaccess

[Certara @Certara]

Although AMCP Nexus 2020 doesn't start until next week, registrants can view our posters now, one of which was awarded the prestigious gold ribbon by AMCP earlier this year. Learn more about our posters: https://t.co/64ElA2tPMx
#AMCPNexus

[Certara @Certara]

🚨 LAST CHANCE TO REGISTER! Join Certara Evidence & Access U.S. Access Strategy experts Maximilian Vargas, PhD, MBA and Barbara Pannone tomorrow, Oct. 8 at 11AM EST for a special webinar on payment pressures in U.S. Specialty. Register now: https://t.co/vLqwFd0WFm

#marketaccess

[Certara Evidence & Access @CertaraAccess]

Our whitepaper series, "Disruptive Trends in U.S. Market Access 2020 - 2023" was based on research with leading U.S. managed care stakeholders, representing a total of nearly 200 million U.S. lives. Read the #pressrelease: https://t.co/rxdV2Gwf2Y #marketaccess

[Certara @Certara]

#PressRelease - We are excited to share that @CertaraAccess has published a series of four white papers on key trends poised to shape U.S. market access. To read the full press release, visit: https://t.co/s5GdSyIYZv